Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $31.86, signifying a +1.01% move from its prior day's close.

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

Most Super Bowl commercials aim to entertain. A minute-long Big Game ad from telehealth company Hims & Hers Health might do ...

Hims & Hers Health (NYSE: HIMS) is a relatively young company addressing age-old healthcare challenges by offering ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $31.86 which represents a slight increase of $0.32 or 1.01% from the prior close of $31.54. The stock opened at $31.9 and ...

A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...